Momenta Pharmaceuticals Appoints Young T. Kwon as Vice President, Business Development

Momenta Pharmaceuticals Appoints Young T. Kwon as Vice President, Business Development


CAMBRIDGE, Mass., Jan. 4, 2011 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Young T. Kwon, Ph.D., has been appointed the Company's new Vice President of Business Development.

Craig A. Wheeler, CEO of Momenta, commented, "We are delighted to have Young join our team. His valuable industry experience will be critical to us as we evaluate collaboration opportunities and execute on our business development initiatives. Building on his strong background in biologic products, Young will also play a key strategic leadership role as we advance our follow-on biologics product portfolio."

Prior to joining Momenta, Dr. Kwon was Senior Director, Business Development, at Biogen Idec where he was responsible for leading corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. Dr. Kwon received his bachelor's degree in biology from the Massachusetts Institute of Technology and his Ph.D. in biological chemistry and molecular pharmacology from Harvard University. He has co-authored numerous peer-reviewed publications in the area of neurobiology.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

CONTACT: Momenta Pharmaceuticals, Inc.

         Beverly Holley, Director, Investor Relations

         617-395-5189

         [email protected]: Momenta Pharmaceuticals


News Provided by Acquire Media


 

Suggested Articles

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .

OrbiMed, Novartis Venture Fund and RA Capital Management have joined forces to fund and help launch GentiBio.